Business Wire

SHIPPEO

13.6.2022 10:02:09 CEST | Business Wire | Press release

Share
Shippeo and Everysens Enhance Intermodal Visibility Offering With Strategic Partnership

Shippeo , a leading provider of global and multimodal shipment visibility, has partnered with Everysens , a leader in rail and intermodal transport management systems, to enhance their multimodal transport visibility offering. Everysens will provide Shippeo with the most reliable rail ETA available on the market, based on real-time data from satellite tracking and rail operators.

The two-way partnership allows Everysens to also benefit from Shippeo’s large network of road and ocean carriers, providing high quality shipment tracking data to rail and intermodal shippers and their customers. By sharing container events for ocean shipments, as well as highly accurate and reliable road freight ETAs , Everysens can better anticipate impacts on rail logistics .

In turn, Shippeo receives a stream of rail events from Everysens , including ETAs, GPS positions and loading statuses. Everysens provides ETAs for both full trains and single wagons ; a unique capability within the market. The improved visibility across all types of rail transport will be available globally for Shippeo customers. In addition, Everysens covers the full transport process , including tendering, collaborative smart planning, freight letters and CO2 emissions.

By integrating their respective shipment ETAs, both companies are able to offer their customers improved end-to-end visibility in a single offering, creating new opportunities for supply chain convergence and benefitting shippers with a higher level of supply chain transparency and optimised logistics flows.

“As shippers face more and more supply chain challenges around the world as a result of disruptive global events, they want to know when their shipments will reach their final destination,” explains Lucien Besse, COO and Co-founder at Shippeo. “With sustainability playing an increasingly important role in transportation management, rail is becoming a popular means of intermodal transport. However, visibility over rail shipments has not been easy for shippers to achieve. The partnership between Shippeo and Everysens increases shippers’ trust in rail and multimodal deliveries , providing them with critical monitoring milestones, as well as the ability to measure and improve their processes.”

“Rail is already an important part of multimodal logistics. Effects of the EU Green Deal are quickly positioning rail further as the future of freight,” says Dr. Youness Lemrabet, CEO and Founder of Everysens. “The target is clear: 30% modal share for rail by 2030, with an estimated impact of 290 million tons of CO2 saved . To reach this, rail needs newcomers, for whom intermodal is the primary entry point. With this partnership, we can connect the dots between rail and first- and last-mile transport modes, to make modal shift truly happen .”

For more information

About Shippeo

Shippeo is a global leader in real-time multimodal transportation visibility, helping major shippers and logistics service providers operate more collaborative, automated, sustainable, profitable, and customer-centric supply chains with highly accurate, real-time operational visibility and perfect workflow orchestration. Their Multimodal Visibility Network integrates with more than 875 TMS, telematics and ELD systems, enabling Shippeo’s platform to provide instant access to real-time shipment tracking across all transport modes, in a single portal, through an intuitive user experience. A proprietary and industry-leading machine learning algorithm offers unmatched ETA accuracy, allowing supply chain companies to quickly anticipate problems, proactively alert customers, efficiently manage exceptions with collaborative workflows, and accurately measure CO2 and GHG emissions from supply chain transport. Hundreds of customers, including global brands like Coca-Cola HBC, Carrefour, Renault Group, Schneider Electric, Total, Faurecia, Saint-Gobain and Eckes Granini, trust Shippeo to track more than 28 million shipments per year across 75 countries. Learn more at www.shippeo.com
LinkedIn , Facebook , Twitter

About Everysens

Decarbonising transport, one train at a time. Everysens offers the first Transport Visibility & Management System (TVMS): a TMS specialised in the predictive planning of your rail and intermodal transport by integrating real-time visibility into your processes. This collaborative tool simplifies exchanges between the logistics operator, shippers, carriers and customers for a better execution of transport flows. Integrated with more than 40 rail operators and wagon rental companies, Everysens brings the whole rail and intermodal ecosystem to their industrial customers. Everysens is trusted by the largest chemical, cereals, steel and construction materials companies (among which Arkema, TotalEnergies, ArcelorMittal, HeidelbergCement, CRH) to empower their CO2 and modal shift strategies thanks to simpler rail processes.

Learn more at www.everysens.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye